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Institute GmbH, Berlin, GermanyIntroduction: We present a new approach to evaluate the importance of ambulatory nephrology care in
patients with chronic kidney disease (CKD).
Methods: An anonymized health claims database of German insurance companies was searched in a
retrospective analysis for patients with CKD using the codes of the International Classiﬁcation of Diseases,
10th German modiﬁcation. A total of 105,219 patients with CKD were identiﬁed. Patients were assigned to
the group “timely referral,”when nephrology care was present in the starting year 2009, or initiated during
the following 3 years in CKD1–4. Using frequency matching for age and gender, 21,024 of the late referral
group were matched with the equal number of patients in the timely referral group. Hospital admission
rates, total treatment costs, and kidney function (change in CKD stages, start of dialysis, mortality) were
documented each year during the 4-year follow-up.
Results: Hospital admission rates (110%–186%) and total treatment costs (119%–160%) were signiﬁcantly
higher (P < 0.03) in late referral compared with timely referral. In the timely referral group, signiﬁcantly
more patients did not change their CKD stage (65%–72.9% vs. 52%–64.6%, P < 0.05) compared with late
referral. Starting in CKD3 more patients tended to start dialysis in 1 year in timely referral (1.9  0.6 vs.
1.0  0.4, P ¼ 0.1). In contrast, death rates were signiﬁcantly higher in the late referral group (18.8  1.8%
vs. 6.7  0.4%, P ¼ 0.0001).
Discussion: Timely referral to outpatient nephrology care is associated with slowed disease progression,
less hospital admissions, reduced total treatment costs, and improved survival in patients with CKD.
Kidney Int Rep (2016) -, -–-; http://dx.doi.org/10.1016/j.ekir.2016.09.062
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C hronic kidney disease (CKD) is an important riskfactor of all-cause as well as cardiovascular mortal-
ity, the incidence of acute renal failure, and the pro-
gression to end-stage kidney disease in the need of
renal replacement therapy. Similar to other industrial-
ized countries such as Norway, Canada, and the USA,
the prevalence of CKD3–5 (glomerular ﬁltration
rate < 60 ml/min per 1.73 m2) in Germany is approxi-
mately 5% of the population.1–3 Arterial hypertension,
diabetes, and cardiovascular diseases are the main
causes of progressive loss of kidney function. Accord-
ing to epidemiologic studies, patients with CKD3–5spondence: Gerhard Lonnemann, Verband Deutsche Nier-
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International Reports (2016) -, -–-in nonspecialized medical care lose approximately
5 ml/min per year of glomerular ﬁltration rate.4 Several
studies suggest that the involvement of nephrologists
in patient care starting at CKD3 (timely referral) results
in a signiﬁcant reduction of CKD progression to less
than 2 ml/min per year.5 Therefore, timely referral to
nephrology care with optimized conservative and med-
ical treatment prolongs the time until start of renal
replacement therapy and may reduce signiﬁcantly
long-term treatment costs of CKD.
In this study, we choose a new approach to evaluate
the importance of ambulatory nephrology care. Using
the database of German health insurance companies, a
cohort of patients was deﬁned. Deﬁnition criteria were
age, gender, CKD stage, and whether or not nephrology
care had been introduced. We analyzed the association
between outpatient nephrology care and (i) quality of
disease coding, (ii) follow-up, (iii) rate of hospitalization,1
CLINICAL RESEARCH G Lonnemann et al.: Referral to Nephrology, Costs, and Mortalityand (iv) mortality. Speciﬁcally, this paper evaluates
the hypothesis that timely referral to nephrology
care slows progression of CKD and reduces treatment
costs.
METHODS
The study sample consisted of claims data from the
German Health Risk Institute, which includes anony-
mized claims of approximately 80 different health
insurance providers (of approximately 130 in Germany)
and comprises the utilization of services on an anony-
mous patient-by-patient individual level. This research
database comprises more than 3.3 million anonymized
covered lives. The sample is representative for the
German population in terms of age and gender.6
This database has been analyzed for the presence of
CKD using the codes of the International Classiﬁcation
of Diseases, 10th German modiﬁcation (ICD-10-GM).
The ICD-10-GM allows us to identify the presence of
CKD in general by the code N18.9. In addition, the CKD
stages 1–5 can be indicated (N18.81, N18.82, N18.83,
N18.84, N18.85 for the respective CKD stages until
2009; N18.1, N18.2, N18.3, N18.4, N18.5 for the
respective CKD stages since 2010). Dialysis therapy in
CKD5 can be indicated by adding codes Z49.*, Z99.2,
EBM digits 40800–40808, 40812, 40813, 40820–40823,
or OPS Code (ICPM) 8-854 to N18.5.
The inclusion criteria of this retrospective analysis
were: (i) the presence of CKD stages 1–5 or dialysis
therapy during the 4 years of observation from 2009 to
2012 in adults (age > 18 years), (ii) at least one
approved documentation of CKD stages 3–5 (N18.3,
N18.4, N18.5) in ambulatory or inpatient care, and
(iii) start of dialysis (Z49.*, Z99.2) in ambulatory or
inpatient care. The exclusion criteria were: (i) loss of
health insurance and (ii) loss of data during the
observational period.
According to the inclusion criteria, all patients must
have had at least once a documented CKD stage 3, 4, or
5 during the 4 years of observation. Using the pseu-
donyms, patients were tracked back to the ﬁrst year of
observation, 2009. Patients who had their ﬁrst docu-
mentation of a CKD stage during the years 2010–2012
could have no CKD at all or no speciﬁed CKD stage
in 2009.
To describe progression of CKD over time, the CKD
stage had to be documented at least once a year. If
different CKD stages were recorded in 1 year, the most
advanced stage was used for analysis.
Timely versus late nephrology care was determined
by documentation of care by a nephrologist during the
4-year study period. If nephrology care was received,
the time point of ﬁrst contact to a nephrologist was
recorded.2Patients were assigned to group 1 “timely referral”
(i) when information on CKD stage was available and
nephrology care was present in 2009, or (ii) when during
follow-up until 2012 start of nephrology care was
documented in CKD1–3. Group 2 “late referral” included
(i) all patients with a known CKD stage including clinical
dialysis but without ambulatory nephrology care in
2009, (ii) no contact to a nephrologist throughout the
study period, or (iii) start of ambulatory nephrology care
in CKD5 or on dialysis in 2010–2012.
Using these deﬁnitions, n¼ 105,219 patients fulﬁlled
the inclusion criteria of our observation, n ¼ 21,024
patients were assigned to timely referral and n¼ 84,195
patients to late referral. In the timely referral group,
n¼ 8771women, age (mean SD) 70.9 12.1 years, and
n ¼ 12,253 men, age 68.9  12.0 years, were inclu-
ded. Frequency matching for gender and age (5-year
intervals) was performed to demographically adjust
n ¼ 21,024 patients of the late referral group to the
timely referral cohort. We used the age when stage
CKD3 or worse was documented for the ﬁrst time
(Figure 1).
After adjustment of the 2 cohorts, patients were
grouped according to available information on the CKD
stage.
As shown in Table 1, in the ﬁrst year of observation
(2009), the mean age and gender were comparable in
both timely and late referral groups at all stages of
CKD. The number of patients without speciﬁed infor-
mation on the CKD stage (“no CKD” and “unknown”)
was higher in the late referral group (n ¼ 12,213,
58.0%) than in the timely referral group (n ¼ 8381,
39.9%). There were 4 times more patients on dialysis in
the timely than in the late referral group.
As shown in Table 2, during the starting year 2009,
considerable numbers of patients died before the end of
2009; for timely and late referral, n ¼ 527 and n ¼ 926,
respectively. Only the surviving patients in the 2
groups, n ¼ 20,515 (timely) and n ¼ 20,098 (late), were
included in the follow-up study.
During follow-up, changes in the CKD information
were documented at 3 time points comparing 1-year
periods 2009/2010, 2010/2011, and 2011/2012. In case
the CKD stage changed during 1 year, the most
advanced stage was used for analysis.
Table 3 shows the distribution of timely referral
patients during the ﬁrst transition from 2009 to
2010. For example, n ¼ 5759 patients started in CKD3.
Some patients lost detailed CKD information and
were grouped in “no CKD” (n ¼ 1007) or “unknown”
(n ¼ 818) in 2010, leading to n ¼ 3934 patients who
kept speciﬁc information on their CKD stage in 2010.
For subsequent analyses, only patients who started
the year with a speciﬁed CKD stage (CKD1–5 orKidney International Reports (2016) -, -–-
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Figure 1. Frequency matching for gender and age using 5-year intervals. The paired bars represent the percentage of patients in the particular
age group. Total numbers of women and men and mean ages  SD are given.
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The total number of patients in the timely referral
group in transition from 2009 to 2010 adds up to
n ¼ 9430 patients (Table 3).Table 1. Distribution of chronic kidney disease (CKD) stages in the 2
study groups in 2009
CKD stage
Timely referral Late referral
Mean age
(yr ± SD)
Female
(%)
Patient
number
Mean age
(yr ± SD)
Female
(%)
Patient
number
No CKD 67.8  11.4 43.0 7,084 67.6  12.1 44.7 11,423
CKD stage
not speciﬁed
69.6  11.5 37.6 1,297 70.6  10.8 35.4 790
CKD1 67.7  12.2 40.9 237 69.9  11.4 35.2 236
CKD2 69.5  11.2 37.4 1,282 70.3  10.6 35.1 972
CKD3 69.4  11.3 40.8 5,849 69.4  11.5 38.6 5,562
CKD4 72.1  11.8 49.3 1,690 71.2  12.3 44.8 946
CKD5 65.4  14.4 43.5 580 64.3  14.7 37.8 368
Dialysis 66.6  14.3 39.6 3,005 61.1  15.4 35.2 727
Total number 21,024 21,024
Kidney International Reports (2016) -, -–-Stable kidney function is deﬁned as the unchanged
CKD stage in transition from one year to the next. In
the ﬁrst transition 2009/2010, the numbers of patients
with stable function in CKD3, CKD4, and CKD5 are
depicted in bold numbers (Table 3). These 3 numbers
add up to 3723, which represents 65% of all patients
with CKD3–5 in the timely referral group during
the ﬁrst transition (see Table 3). Similar tablesTable 2. Stages of chronic kidney disease (CKD) in the end of the
starting year 2009
Stage Timely referral Late referral
Last stage in 2009
(start year)
No CKD 7,084 11,423
Unknown 1,297 790
CKD1 237 236
CKD2 1,282 972
CKD3 5,759 5,017
CKD4 1,595 728
CKD5 548 316
Dialysis 2,695 616
Died 527 926
Total n ¼ 21,024 n ¼ 21,024
3
Table 3. Number of timely referral patients in the transition 2009/2010 with known chronic kidney disease (CKD) stage
2010
No CKD Unknown CKD1 CKD2 CKD3 CKD4 CKD5 Dialysis Died Sum
2009 No CKD 4243 369 66 277 1868 116 13 54 78
Unknown 84 550 11 57 420 73 13 44 45
CKD1 45 38 42 20 80 5 1 3 3 154
CKD2 228 142 23 288 462 66 12 22 39 912
CKD3 1007 818 52 283 2842 347 40 102 268 3934
CKD4 113 130 5 33 197 697 62 176 182 1352
CKD5 68 42 4 18 60 62 184 77 33 438
Dialysis 28 27 1 6 17 29 36 2167 384 2640
Total 9430
Bold numbers add up to 3723, which represents 65% of all patients with CKD3–5 in the timely referral group during the ﬁrst transition.
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2010/2011 and 2011/2012 in both groups (data not
shown).
As shown in Table 4, compared with the timely
referral group, twice as many patients in the late referral
group lost speciﬁc CKD information during all 3 time
periods. However, coding of CKD information improved
during the following years resulting in lower numbers of
patients with lost data in both groups, 12.5% and 27.8%
in the timely and late referral groups, respectively.
Comorbidities were listed throughout the study
period when CKD stage 3 or higher was coded for the
ﬁrst time.
Data on the hospital admission rates as well as the
total costs for in-hospital care, outpatient care, and
medication are expressed per patient per year. Total
costs include all invoices issued by hospitals, ambula-
tory care, and pharmacies covered by the health
insurance. In Germany, nonmedical costs for dialysis
care (nursing, disposals) are covered by ﬁxed prices per
week that are excluded from these calculations. The0
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Figure 2. Hospital admission rates per patient per year. Bars represent the
5 and dialysis treatment. P values are given for comparison of the paired
were, for CKD3, n ¼ 6724 (5759/8151) versus n ¼ 5137 (4219/6128); for CKD4
(361/548) versus n ¼ 259 (181/316); and for hemodialysis, n ¼ 2593 (2521/2
4results are expressed as median (min/max) of the
4 years, 2009 through 2012.Statistics
Results are expressed as median (min/max) in Figures 2
and 3 or as means  SD in Figure 5. To describe sta-
tistically signiﬁcant differences, Student’s t-test for
paired observations was employed. A Kaplan-Meier
analysis was done on the probability of survival in
patients with CKD3 starting in 2009 (Figure 6).RESULTS
Comorbidities
The predominant comorbidities were identiﬁed by ICD
coding during the year when CKD3 or higher was
coded for the ﬁrst time (Table 5).
Chronic heart failure and disturbances of acid-base
status and electrolyte plasma levels were more
frequently noted in the late referral group. All other
comorbidities were comparable in both the groups.CKD5 dialysis
 stages
Median Ɵmely
Median late
P = 0.025
P = 0.11
ssion rate
median (min/max) of n ¼ 4 years (2009–2012) for patients with CKD3–
bars. The median (min/max) numbers of patients timely versus late
, n ¼ 1682 (1395/1988) versus n ¼ 1064 (728/1392); for CKD5, n ¼ 447
695) versus n ¼ 778 (616/909). CKD, chronic kidney disease.
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Figure 3. Total costs per patient per year in Euro (V). Bars represent the median (min/max) of n ¼ 4 years (2009–2012) for patients with CKD3–5
and dialysis treatment. P values are given for comparison of the paired bars. For numbers of patients in the analyzed groups, see the legend of
Figure 2. CKD, chronic kidney disease.
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The hospital admission rate per patient per year
throughout the 4-year observation was signiﬁcantly
higher in the late referral group for all patients with
CKD3–5 (Figure 2). Patients with CKD3 had a hospital
admission rate of (median [min/max]) 0.95 (0.88/1.04)
and 1.77 (1.57/1.85) (P ¼ 0.00003) in the timely and late
referral groups, respectively. In CKD4, the admission
rates were 1.35 (1.31/1.42) versus 2.07 (1.95/2.15)
(P ¼ 0.00001); in CKD5, the admission rates were 1.16
(0.96/1.26) versus 1.62 (1.20/1.75) (P ¼ 0.025) in favor
of the timely referral group. For patients on dialysis
treatment, the admission rate in the late referral group
tended to be higher than in the timely referral group,
1.69 (1.65/1.71) versus 1.87 (1.61/1.93) without reach-
ing statistical signiﬁcance (P ¼ 0.11).
Total Treatment Costs
During the 4 years of observation, the expenses for
hospital care, ambulatory care, and medication were
added up to total costs per patient per year (Figure 3).
In patients with CKD3, the median (min/max) costs in
the timely referral group were 8149 (7375/8504) V
versus 13,054 (11,409/13,223) V in the late referral
group (P ¼ 0.00008). For patients with CKD4, expenses
increased and were signiﬁcantly higher in the late
referral group: 10,953 (9413/11,587) V (timely) versus
15,526 (14,922/16,563) V (late) (P ¼ 0.0002). In patients
with CKD5, the difference between the 2 groups was
not signiﬁcant: 12,634 (11,040/13,035) V versus 15,085Kidney International Reports (2016) -, -–-(10,633/16,069) V (P ¼ 0.199). Interestingly, patients
on hemodialysis in the late referral group caused
signiﬁcantly higher expenses for the health insurance
companies: 20,991 (20,750/21,166) V (timely) versus
26,747 (23,105/27,526) V (late) (P ¼ 0.002).
Patients With Stable CKD Stages
In patients with CKD3–5, the number of patients with
stable disease was 8% to 13% higher in the timely than
in the late referral group (Figure 4). In the transition
period 2009/2010, 65% of patients in the timely referral
group versus 52% in the late referral group kept their
CKD stages. These differences persisted during the
following years: 71.5% (timely) versus 60.3% (late) in
2010/2011 and 72.9% (timely) versus 64.6% (late) in
2011/2012 (Figure 4).
CKD Progression and Mortality
In patients with initial CKD3, timely referral to a
nephrologist resulted in stability of their CKD stage
(75.1  2.6% in the timely referral vs. 63.0  6.3% in
the late referral, P ¼ 0.037). As shown in Figure 5, the
death rate was signiﬁcantly higher in the late referral
group than in the timely referral group (18.8  1.8%
vs. 6.7  0.4%, P ¼ 0.0001). The percentages of
patients improving to CKD stage 1or 2 as well as those
deteriorating to CKD stage 4 or 5 were low in both
groups without signiﬁcant differences (Figure 5).
The percentage of patients starting dialysis tended to
be higher in the timely referral group (1.9  0.6 vs.
1.0  0.4%, P ¼ 0.10) without reaching signiﬁcance.5
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Figure 4. Total number of patients with stable kidney function in transition from one year to the next. Mean percentages of patients with stable
disease in the 2 groups are given in the table underneath. P values are depicted. CKD, chronic kidney disease.
CLINICAL RESEARCH G Lonnemann et al.: Referral to Nephrology, Costs, and MortalitySimilar results were seen in CKD4 (not shown). More
patients with timely referral maintained their stage
compared with the late referral group (57.2  5.0% vs.
46.6  7.0%, P ¼ 0.1). Also the death rate followed
a similar pattern being signiﬁcantly higher in the
late referral group (23.1  3.5% vs. 12.6  0.5%,
P ¼ 0.006) and more patients started dialysis in
the timely referral group (11.4  2.0% vs. 6.4  0.2%,
P ¼ 0.013).
Probability of Patient Survival
A Kaplan-Meier analysis on the probability of survival
was done in patients with CKD3 starting in 2009Table 4. Loss of speciﬁed chronic kidney disease (CKD) information durin
2009/2010
Timely referral Late referral
Start with CKD information: total number of patients 12,116 7885
Loss of CKD information: number of patients (%) 2686 (22.17) 3597 (45.62)
Remaining number of patients for analysis (%) 9430 (77.83) 4288 (54.38)
6(Figure 6). The numbers at risk were n ¼ 5759 and
n ¼ 5017 for timely referral and late referral, respec-
tively. The proportion of patients surviving in the
3-year follow-up was signiﬁcantly higher in the timely
referral group with a log rank of P ¼ 0.0001 (Figure 6).
DISCUSSION
In this paper, we analyzed the anonymized database of
German health insurance companies to describe the
importance of timely outpatient nephrology care in
patients with CKD with respect to hospitalization,
treatment costs, progression of kidney disease, and
mortality.g follow-up
2010/2011 2011/2012
Timely referral Late referral Timely referral Late referral
11,533 7033 13,237 8343
1477 (12.80) 2183 (31.00) 1659 (12.53) 2323 (27.84)
10,056 (87.20) 4850 (69.00) 11,578 (87.47) 6020 (72.16)
Kidney International Reports (2016) -, -–-
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by the ICD-10 codes classifying the CKD stages. Laboratory
data on kidney function, for example, according to
the chronic kidney disease epidemiology collaboration
formula, were not available. It became obvious that
speciﬁc ICD coding of CKD stages was done much more
thoroughly in the timely referral group (Table 1) resulting
in 60.1% and 41.9% of patients in timely versus late
referral with detailed information on the CKD stages in
2009. During the following 3 years of observation (2010–
2012), coding of the CKD stage gradually improved
resulting in decreased loss of CKD information (Table 4)
increasing the sample size and thereby the power of
the study. Explanations for these improvements remain
speculative. Possibly, acceptance of detailed CKD coding
improved with the modiﬁcation of the ICD-10
system in 2010. This modiﬁcation includes increasing
reimbursements with higher speciﬁed CKD codes.
Continuous precise coding of the CKD stage as well
as documentation of mortality is essential to obtainKidney International Reports (2016) -, -–-reliable longitudinal data sets. With respect to patients
with CKD, this data documentation seems to be better
done by nephrologists than by nonspecialists. Although
the loss of speciﬁc CKD information during follow-up
may weaken the value of the results, the analysis was
carried out in 13,718 (2009/2010) to 17,598 (2011/2012)
patients, which should result in a fairly powerful study.
After adjustment for gender and age, comorbidities
were documented in the year when CKD stage 3 or worse
was reached (Table 5). Almost all patients suffered from
hypertension and 46% to 49% had diabetes. Interest-
ingly, atrial ﬁbrillation and disturbances of acid-base
status and electrolytes appear to be more common in
the late referral group. This may indicate that nephrol-
ogists pay more attention to these disturbances and treat
metabolic acidosis by prescribing oral bicarbonate more
often than nonspecialists. Taken together, the study
cohort with a mean age of 70.0  12.1 years, 42% fe-
males, and the distributed comorbidities represents the
typical population with the risk of progressive CKD.37
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Hospital Admission Rates and Reduced
Treatment Costs
The hospital admission rates for any medical reason as
well as the total expenses for hospital care, outpatient
care, and medication were compared per CKD stage and
year in the 2 study groups (Figures 2 and 3). The
hospital admission rate was signiﬁcantly higher in the
late referral group than in the timely referral. It
remains unclear why in both groups the admission rate
in CKD5 tended to be lower than in CKD4. The
threshold between CKD4 and CKD5 is an estimated
glomerular ﬁltration rate of 15 ml/min. The frequency
of hospital admissions may not be signiﬁcantlyTable 5. Comorbidities in the 2 study groups
Diagnoses
Timely referral
n [ 20,962 (%)
Late referral
n [ 20,628 (%)
Hypertension 93 87
Hypertensive cardiac disease 24 23
Chronic heart failure 36 44
Chronic ischemic heart disease 45 46
Atrial ﬁbrillation 24 30
Diabetes mellitus type 2 49 46
Disturbances of acid-base status and electrolytes 25 35
Adiposity 32 30
Lipid disorders 66 59
n, patient number.
8different between CKD4 and nondialysis CKD5. Simi-
larly, the total treatment costs were signiﬁcantly higher
when patients with CKD were in the late referral group.
The health care costs for dialysis patients seem to be
low. This is explained by the fact that expenses for
nursing, overhead, and single-use dialysis material are
not included. These results are in agreement with
published retrospective analyses on the effect of timely
referral to nephrology care on treatment costs.7,8
Those data strongly indicate that outpatient
nephrology care should be initiated at the latest in
patients with CKD stage 3 to reduce the need of hospital
care and total treatment costs.
Timely Referral Is Associated With Reduced
Disease Progression and Mortality in CKD
We also analyzed improvement, stabilization, and
progression of CKD and mortality comparing the dis-
tribution of those parameters in the CKD stages from
one year to the next. Starting with 2009, in all transi-
tions, timely referral as compared with late referral
resulted in approximately 13% more patients who
remained in their CKD stages 3–5. In other words, pa-
tients in nephrology care had more often stable kidney
function indicating slower progression of renal disease.
Our data conﬁrm results of the German CKD registry
demonstrating that approximately 70% patients withKidney International Reports (2016) -, -–-
G Lonnemann et al.: Referral to Nephrology, Costs, and Mortality CLINICAL RESEARCHCKD3–4 in outpatient nephrology care had a stable CKD
stage.9
Only a few patients improved to better CKD stages
without signiﬁcant differences between the 2 groups.
In the timely referral cohorts, more patients started
hemodialysis treatment, but death rates were signiﬁ-
cantly lower in the timely referral group. These data
are supported by the Kaplan-Meier analysis on the
probability of survival in patients starting in CKD3 in
2009. After 4 years of follow-up, approximately 85%
of patients in the timely referral group versus only
77% in the late referral group survived (log rank,
P ¼ 0.0001). These data suggest that patients in
outpatient nephrology care may survive longer, in part
for the price of starting extracorporeal renal replace-
ment therapy.
The strength of the presented retrospective analysis
is based on the relatively high number of patients
identiﬁed in an anonymized database of 80 health
insurance providers. The study cohort including more
than 42,000 patients seems to be representative for the
German society in respect to age and gender distribu-
tion, because the CKD registry shows similar numbers.9
LIMITATIONS
This being an observational study, associations can be
reported. Also the diagnostic performance of ICD-10
codes is not known, which may be a limitation. We
pointed out that correct coding and the documentation
of changes in CKD stages are improved but still not
complete in nephrology care. Another limitation is the
lack of data on proteinuria. Future studies should use
the KDIGO classiﬁcation instead of CKD coding only. A
further disadvantage in analyzing an anonymized
database is that longitudinal data are not available.
Only changes in CKD stages in the deﬁned study
groups are documented with signiﬁcant differences
between the timely and late referral groups during the
transition from one year to the next.
Keeping in mind that our analysis of a very large
database of health insurance companies is a new
approach to perform a retrospective study, our results
are in agreement with retrospective clinical studies
demonstrating that the early initiation of nephrology
care slows down progression of CKD.5,10,11 Mortality in
incident dialysis patients is signiﬁcantly reduced when
outpatient nephrology care is initiated at least 3–12
months before the start of renal replacement ther-
apy.12,13 Improved mortality is, at least in part, due to a
timely creation of a native arteriovenous ﬁstula before
the start of hemodialysis.14,15 Althoughwe did not study
the role of vascular access on survival of hemodialysis
patients, our data add evidence that timely referral toKidney International Reports (2016) -, -–-nephrology care improves survival of patients with
CKD. In addition, the presented data suggest that
hospital admission rates and total treatment costs
are reduced as well when nephrology centers are
involved in the treatment of patients with CKD stage 3
or worse.
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